Literature DB >> 23749644

Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation.

Rodrigo Hess Michelini1, Teresa Manzo, Tabea Sturmheit, Veronica Basso, Martina Rocchi, Massimo Freschi, Joanna Listopad, Thomas Blankenstein, Matteo Bellone, Anna Mondino.   

Abstract

Vaccination can synergize with transplantation of allogeneic hematopoietic stem cells to cure hematologic malignancies, but the basis for this synergy is not understood to the degree where such approaches could be effective for treating solid tumors. We investigated this issue in a transgenic mouse model of prostate cancer treated by transplantation of a nonmyeloablative MHC-matched, single Y chromosome-encoded, or multiple minor histocompatibility antigen-mismatched hematopoietic cell preparation. Here, we report that tumor-directed vaccination after allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion is essential for acute graft versus tumor responses, tumor regression, and prolonged survival. Vaccination proved essential for generation of CD8(+) IFN-γ(+) tumor-directed effector cells in secondary lymphoid organs and also for IFN-γ(+) upregulation at the tumor site, which in turn instructed local expression of proinflammatory chemokines and intratumoral recruitment of donor-derived T cells for disease regression. Omitting vaccination, transplanting IFN-γ-deficient donor T cells, or depleting alloreactive T cells all compromised intratumoral IFN-γ-driven inflammation and lymphocyte infiltration, abolishing antitumor responses and therapeutic efficacy of the combined approach. Our findings argue that posttransplant tumor-directed vaccination is critical to effectively direct donor T cells to the tumor site in cooperation with allogeneic hematopoietic cell transplantation. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23749644     DOI: 10.1158/0008-5472.CAN-12-3464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies.

Authors:  Haoqing Shi; Xiangjie Qi; Bin Ma; Yanwei Cao; Lina Wang; Lijiang Sun; Haitao Niu
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 2.  Cellular immunotherapies for cancer.

Authors:  Pedro Berraondo; Sara Labiano; Luna Minute; Iñaki Etxeberria; Marcos Vasquez; Alvaro Sanchez-Arraez; Alvaro Teijeira; Ignacio Melero
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

Review 3.  Prostate cancer susceptibility and growth linked to Y chromosome genes.

Authors:  Riddhi Patel; Ahmad O Khalifa; Ilaha Isali; Sanjeev Shukla
Journal:  Front Biosci (Elite Ed)       Date:  2018-03-01

4.  Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.

Authors:  C Göbel; F Breitenbuecher; H Kalkavan; P S Hähnel; S Kasper; S Hoffarth; K Merches; H Schild; K S Lang; M Schuler
Journal:  Cell Death Dis       Date:  2014-12-11       Impact factor: 8.469

5.  A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

Authors:  C Botta; M T Di Martino; D Ciliberto; M Cucè; P Correale; M Rossi; P Tagliaferri; P Tassone
Journal:  Blood Cancer J       Date:  2016-12-16       Impact factor: 11.037

6.  Alteration of Adaptive Immunity in a Colorectal Peritoneal Carcinomatosis Model.

Authors:  Rongchen Shi; Wei Xiang; Xia Kang; Lili Zhang; Jinping Wang; Hongming Miao; Fengtian He
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

Review 7.  Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes.

Authors:  Matteo Bellone; Arianna Calcinotto
Journal:  Front Oncol       Date:  2013-09-11       Impact factor: 6.244

8.  Tumor-targeting vaccination instructs graft-vs.-tumor immune responses.

Authors:  Teresa Manzo; Rodrigo Hess Michelini; Tabea Sturmheit; Veronica Basso; Matteo Bellone; Anna Mondino
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

Review 9.  To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.

Authors:  Anna Mondino; Teresa Manzo
Journal:  Front Immunol       Date:  2020-08-27       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.